Showing results (391-400 of 478) with videos related to
Sort By:
Pageof 48
JACC. Cardiovascular Interventions|August 7, 2017
Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS StudyUsman Baber, Jaya Chandrasekhar, Samantha Sartori, et al.The New England Journal of Medicine|February 5, 2015
Efficacy of a device to narrow the coronary sinus in refractory anginaStefan Verheye, E Marc Jolicœur, Miles W Behan, et al.European Heart Journal. Acute Cardiovascular Care|July 17, 2023
Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS studyMauro Chiarito, Davide Cao, Samantha Sartori, et al.The American Journal of Cardiology|September 4, 2019
Association Between Hypertension, Platelet Reactivity, and the Risk of Adverse Events After Percutaneous Coronary Intervention (From the ADAPT-DES Study)Björn Redfors, Shmuel Chen, Ori Ben-Yehuda, et al.International Journal of Cardiology|June 11, 2011
A randomized, controlled, multi-center trial comparing the safety and efficacy of zotarolimus-eluting and paclitaxel-eluting stents in de novo lesions in coronary arteries: final results of the ZoMaxx II trialWilliam A Gray, Alan C Yeung, Donald E Cutlip, et al.Circulation. Cardiovascular Interventions|September 17, 2017
White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry)Binita Shah, Usman Baber, Stuart J Pocock, et al.Journal of Thrombosis and Thrombolysis|March 30, 2019
Associations between use of prasugrel vs clopidogrel and outcomes by type of acute coronary syndrome: an analysis from the PROMETHEUS registryZhen Ge, Usman Baber, Bimmer E Claessen, et al.JACC. Cardiovascular Interventions|January 8, 2016
Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents)Ajay J Kirtane, Puja B Parikh, Thomas D Stuckey, et al.Journal of the American College of Cardiology|April 16, 2016
Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARISUsman Baber, Roxana Mehran, Gennaro Giustino, et al.European Journal of Preventive Cardiology|March 11, 2026
Mortality score in chronic coronary syndrome: prediction model from the ISCHEMIA trialEliano P Navarese, Giuseppe Talanas, Dean J Kereiakes, et al.Pageof 48